147 related articles for article (PubMed ID: 29299769)
1. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
Righolt CH; Pabla G; Mahmud SM
Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
[TBL] [Abstract][Full Text] [Related]
2. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
3. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
5. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
6. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
7. Health and economic burden of HPV-related diseases in Singapore.
Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of human papillomavirus-related diseases in Italy.
Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
[TBL] [Abstract][Full Text] [Related]
9. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
10. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
[TBL] [Abstract][Full Text] [Related]
11. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
Mizukami A; Kaise T; Van Kriekinge G
Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
13. The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015.
Ki M; Choi HY; Han M; Oh JK
Vaccine; 2018 Jul; 36(31):4633-4640. PubMed ID: 29961603
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
15. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
16. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
17. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
[TBL] [Abstract][Full Text] [Related]
18. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
Brisson M; Van de Velde N; De Wals P; Boily MC
Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
20. Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
Clay PA; Thompson TD; Markowitz LE; Ekwueme DU; Saraiya M; Chesson HW
Vaccine; 2023 Mar; 41(14):2376-2381. PubMed ID: 36907737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]